To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Certain Antipsychotics Increase Metabolic, Cardiovascular Risk Factors URL: http://www.pslgroup.com/dg/2268D6.htm Doctor's Guide July 28, 2008
BETHESDA, Md -- July 28, 2008 -- Some atypical antipsychotics may be more likely than others to cause metabolic and cardiovascular side effects, according to a study published in the August 2008 issue of Schizophrenia Research. The study was based on recent data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. Jonathan Meyer, MD, University of California at San Diego, San Diego, California, and colleagues compared baseline data with those collected 3 months later from 281 CATIE participants who were randomly assigned to treatment with 1 of 5 antipsychotics -- olanzapine, risperidone, ziprasidone, quetiapine, or perphenazine. They found that the prevalence of metabolic syndrome increased the most among patients taking olanzapine, from 35% to 44%, even if they had preexisting metabolic problems. The prevalence of metabolic syndrome decreased for those taking ziprasidone, from 38% to 30%, and remained about the same for risperidone, quetiapine, and perphenazine. Those on olanzapine and quetiapine gained the most weight, with waist size increasing an average of 0.7 inches. Waist size of those taking risperidone grew an average 0.4 inches, while those taking ziprasidone showed no change in waist size. Patients taking perphenazine lost a small amount of weight on average. Olanzapine also was associated with significant increases in fasting triglycerides. Dr. Meyer and colleagues then studied changes in nonfasting triglyceride levels using data from 246 different CATIE participants who had provided nonfasting triglyceride baseline and 3-month data. The researchers found the greatest increase in levels among those taking quetiapine and olanzapine. Among those taking ziprasidone or perphenazine, there was no change in nonfasting triglyceride levels. Levels for those taking risperidone decreased. The researchers conclude that the need for frequent and routine monitoring of metabolic and cardiovascular factors is crucial, especially if patients are taking olanzapine and quetiapine and if they have preexisting metabolic issues. SOURCE: US National Institutes for Mental Health --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.